The math operators module provides an execution environment for Price Series Multiplication operator and related indicators on Ardelyx and Upstream Bio. This view tracks relative price relationships between Ardelyx and Upstream Bio to support structured performance interpretation without implying advice.
The output start index for this execution was zero with a total number of output elements of sixty-one. Ardelyx Price Series Multiplication is a cross multiplication of Ardelyx price series and its benchmark/peer.
Ardelyx Technical Analysis Modules
Most technical analysis of Ardelyx help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Ardelyx from various momentum indicators to cycle indicators. When you analyze Ardelyx charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Ardelyx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. A high-level view of Ardelyx emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 8.32, profit margin of -15.12%. Ardelyx has a market cap of 1.39 B, ROE of -36.21%.
Methodology
Unless otherwise specified, financial data for Ardelyx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Ardelyx (USA Stocks:ARDX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Ardelyx may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Ardelyx inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Ardelyx often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Ardelyx Stock in context:
Ardelyx has a market cap of 1.39 B, operating margin of 4.07%, ROE of -36.21%. Use Trending Equities to explore allocation context. This includes a position in Ardelyx across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.
For more information on how to buy Ardelyx Stock please use our How to Buy Ardelyx Stock guide.Analysis related to Ardelyx should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
The market value of Ardelyx is measured differently than book value, which reflects Ardelyx accounting equity. Ardelyx's market capitalization is 1.39 B. With a P/B ratio of 8.32, the market values Ardelyx well above its book equity. Enterprise value stands at 1.33 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Ardelyx's intrinsic value and market price are different measures derived from different inputs. For Ardelyx, key inputs include a P/B ratio of 8.32, a profit margin of -15.12%, ROE of -36.21%, and revenue of 407.32 M. Trading price represents the transaction level agreed by market participants.